Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E48.49 EPS (ttm)1.46 Insider Own0.10% Shs Outstand2.68B Perf Week0.33%
Market Cap189.55B Forward P/E15.25 EPS next Y4.63 Insider Trans-23.36% Shs Float2.66B Perf Month2.33%
Income3.94B PEG6.09 EPS next Q1.12 Inst Own75.70% Short Float0.75% Perf Quarter16.35%
Sales41.26B P/S4.59 EPS this Y29.20% Inst Trans-1.09% Short Ratio2.42 Perf Half Y31.44%
Book/sh12.12 P/B5.83 EPS next Y8.35% ROA1.50% Target Price72.15 Perf Year8.39%
Cash/sh2.83 P/C24.96 EPS next 5Y7.96% ROE3.90% 52W Range52.83 - 71.57 Perf YTD25.56%
Dividend1.92 P/FCF11847.12 EPS past 5Y-1.90% ROI8.70% 52W High-1.29% Beta0.84
Dividend %2.72% Quick Ratio1.00 Sales past 5Y-3.20% Gross Margin68.00% 52W Low33.73% ATR0.86
Employees69000 Current Ratio1.30 Sales Q/Q5.40% Oper. Margin12.30% RSI (14)63.05 Volatility1.11% 1.17%
OptionableYes Debt/Eq0.72 EPS Q/Q-10.50% Profit Margin3.30% Rel Volume0.66 Prev Close70.78
ShortableYes LT Debt/Eq0.61 EarningsOct 26 BMO Payout377.30% Avg Volume8.21M Price70.65
Recom2.10 SMA201.51% SMA504.92% SMA20017.16% Volume5,386,533 Change-0.18%
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Sep-24-18 02:40PM  OpGen signs deal with New York health department to research superbugs American City Business Journals
09:45AM  Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market Bloomberg
07:47AM  Merck subsidiary plans $48M investment, 115 jobs in Albany area over five years American City Business Journals
07:15AM  With An ROE Of 4.2%, Has Merck & Co Incs (NYSE:MRK) Management Done Well? Simply Wall St.
Sep-21-18 10:43AM  Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda Zacks
12:00AM  How Do Drugs Compete Against Each Other? Motley Fool
Sep-20-18 07:52PM  Flexible labs, co-working space: Big Pharma is rethinking real estate American City Business Journals
04:30PM  Merck Receives Positive CHMP Opinion for DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO (doravirine) in the European Union for the Treatment of HIV-1 Infection Business Wire
10:54AM  Merck or Pfizer: Which is the Better Large-Cap Pharma Stock? Zacks
08:25AM  Galectin stock lifts 15% premarket on early cancer combination trial results MarketWatch
08:00AM  Merck Publishes Corporate Responsibility Report PR Newswire
Sep-19-18 07:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...
Sep-18-18 06:25PM  Accenture, Merck & Amazon AWS Partner for Cloud Platform Zacks
02:57PM  Health care ETF surges toward record in a broad sector rally MarketWatch
08:13AM  Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? Zacks
Sep-14-18 10:02AM  Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus Zacks
08:39AM  Are Options Traders Betting on a Big Move in Merck (MRK) Stock? Zacks
07:21AM  Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal Zacks
Sep-13-18 10:44AM  Merck Gets Priority Review for Yet Another Keytruda sBLA Zacks
08:46AM  Is Merck & Co Incs (NYSE:MRK) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
07:21AM  Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck Bloomberg
Sep-12-18 09:55AM  Merck's Antibacterial Drug Succeeds in Label Expansion Study Zacks
09:45AM  Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus Zacks
09:43AM  Pfizer's Drug Combo Betters Survival in Kidney Cancer Study Zacks
08:34AM  The Zacks Analyst Blog Highlights: Merck, PepsiCo, 3M, Broadcom and Phillips 66 Zacks
06:45AM  FDA Grants Priority Review to Mercks Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS 1%) Business Wire
Sep-11-18 10:39AM  Top Stock Reports for Merck, PepsiCo & 3M Zacks
09:46AM  Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe Zacks
09:13AM  Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer Reuters
08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
06:45AM  Mercks ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Business Wire
Sep-10-18 09:36AM  Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod Zacks
08:04AM  The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson Zacks
07:23AM  Merck's Keytruda clocks up new win as EU approves chemo cocktail Reuters
06:45AM  European Commission Approves Mercks KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations Business Wire
Sep-07-18 10:41AM  Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus Zacks
10:26AM  Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA Zacks
08:35AM  Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress Zacks
08:00AM  Merck to Present at the Morgan Stanley 16th Annual Global Healthcare Conference Business Wire
Sep-06-18 02:12PM  These Hospital Systems Are Aiming To Undercut Biotechs, Drugmakers Investor's Business Daily
12:33PM  How This Player Helps Medical Researchers Ease Drug Discovery Process Investor's Business Daily
09:57AM  Large Cap Pharma Stocks Staging a Comeback in Second Half Zacks
06:30AM  Data from Mercks Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer Business Wire
Sep-05-18 08:05PM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
04:17PM  This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen Investor's Business Daily
10:39AM  Merck's Keytruda Gets Priority Review for Rare Skin Cancer Zacks
07:26AM  [$$] Big Pharma Catches Up With Biotech The Wall Street Journal
06:45AM  Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC) Business Wire
Sep-04-18 09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer Business Wire
Aug-31-18 03:53PM  Merck (MRK) Receives FDA Approval for Two HIV Medicines Zacks
12:42PM  The FDA Approves Merck's Anti-HIV-1 Drugs
10:19AM  Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
08:29AM  The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage Benzinga
Aug-30-18 04:45PM  FDA approves two new HIV drugs from Merck Reuters
04:19PM  FDA approves two new HIV drugs from Merck Reuters
04:05PM  FDA Approves Mercks DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients Business Wire
08:27AM  Mercks Experimental Ebola Shot Seeing Wide Use in Outbreak Bloomberg
06:32AM  Better Buy: Johnson & Johnson vs. Merck Motley Fool
Aug-28-18 06:40PM  3 ETFs for Johnson & Johnson's Healthy Breakout Investopedia
10:27AM  Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol Zacks
Aug-27-18 08:00AM  Today's Research Reports on Trending Tickers: AbbVie and Merck & Co. ACCESSWIRE
Aug-26-18 05:33PM  Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside
Aug-25-18 07:20AM  Better Buy: AbbVie Inc. vs. Merck & Co., Inc. Motley Fool
Aug-24-18 11:41AM  Merck, Pfizer to Benefit From Pharma Surge: MS Investopedia
11:30AM  Merck: Hot Stock May Plunge as Much as 9% Investopedia
10:47AM  Merck, Eisai Get EU Approval for Lenvima Label Expansion Zacks
08:54AM  Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs Zacks
08:27AM  HPV-related cancer rises, despite higher vaccination rates American City Business Journals
07:44AM  Is There An Opportunity With Merck & Co Incs (NYSE:MRK) 24.16% Undervaluation? Simply Wall St.
Aug-23-18 10:00AM  Is Agenus Inc. Stock a Buy? Motley Fool
06:30AM  Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA® (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma Business Wire
Aug-22-18 07:24PM  Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown
11:33AM  Merck Stock Could Rise 30% in Coming Months Investopedia
Aug-21-18 07:25PM  Cramer: Drug stocks' rally doesn't mean a recession is on... CNBC Videos
02:49PM  Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions
12:13PM  5 Companies Hit 52-Week Highs
10:22AM  Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval
09:37AM  Alexandrias Joel Marcus on Medicare-for-all, innovation and his companys Peninsula plans American City Business Journals
09:27AM  Is Merck & Co. a Buy? Motley Fool
08:21AM  Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion Zacks
Aug-20-18 04:05PM  FDA Approves Expanded Label for Mercks KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations Business Wire
01:05PM  Drugmakers Extend Summer Rally as Markets Regain Footing Bloomberg
05:35AM  Alibaba Health to Acquire 14% Stake in Chinese Pharmaceutical Company for $61.3M
Aug-17-18 05:43PM  (OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16) Reuters
10:18AM  Merck, Eisai Get FDA Approval for Lenvima Label Expansion Zacks
09:49AM  4 Mega-Cap Stocks to Buy As Theyre Thrust Into the Spotlight InvestorPlace
09:34AM  Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication Zacks
08:03AM  FDA approves Bristol-Myers' Opdivo for small cell lung cancer Reuters
08:00AM  Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management PR Newswire
08:00AM  Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC) PR Newswire
05:25AM  WHO expects more Ebola cases in Congo, can't reach no-go areas Reuters
Aug-16-18 06:33PM  Japan's Eisai sets price tag of about $16,000 on liver cancer drug Reuters
04:11PM  Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC) PR Newswire
10:08AM  Pain Therapeutics' Shares Rally on Alzheimer's Study Grant Zacks
01:14AM  Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance Reuters
Aug-15-18 03:05PM  FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5% Investor's Business Daily
09:56AM  Agenus (AGEN) Delivering Well on Its Pipeline Candidates Zacks
Aug-14-18 06:39PM  Congo deploys experimental Ebola treatment as cases rise Reuters
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., and Foundation Medicine, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM